Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Circadian Technologies Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Circadian Technologies Limited - Product Pipeline Review - 2014', provides an overview of the Circadian Technologies Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Circadian Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Circadian Technologies Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Circadian Technologies Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Circadian Technologies Limited's pipeline products Reasons to buy - Evaluate Circadian Technologies Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Circadian Technologies Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Circadian Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Circadian Technologies Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Circadian Technologies Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Circadian Technologies Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Circadian Technologies Limited Snapshot 4 Circadian Technologies Limited Overview 4 Key Information 4 Key Facts 4 Circadian Technologies Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Circadian Technologies Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Out-Licensed Products 9 Out-Licensed Products/Combination Treatment Modalities 10 Circadian Technologies Limited - Pipeline Products Glance 11 Circadian Technologies Limited - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Circadian Technologies Limited - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Circadian Technologies Limited - Drug Profiles 13 VGX-100 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 OPT-302 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 VGX-200 Series 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Circadian Technologies Limited - Pipeline Analysis 17 Circadian Technologies Limited - Pipeline Products by Target 17 Circadian Technologies Limited - Pipeline Products by Route of Administration 18 Circadian Technologies Limited - Pipeline Products by Molecule Type 19 Circadian Technologies Limited - Pipeline Products by Mechanism of Action 20 Circadian Technologies Limited - Recent Pipeline Updates 21 Circadian Technologies Limited - Locations And Subsidiaries 25 Head Office 25 Other Locations & Subsidiaries 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables Circadian Technologies Limited, Key Information 4 Circadian Technologies Limited, Key Facts 4 Circadian Technologies Limited - Pipeline by Indication, 2014 6 Circadian Technologies Limited - Pipeline by Stage of Development, 2014 7 Circadian Technologies Limited - Monotherapy Products in Pipeline, 2014 8 Circadian Technologies Limited - Out-Licensed Products in Pipeline, 2014 9 Circadian Technologies Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 10 Circadian Technologies Limited - Phase I, 2014 11 Circadian Technologies Limited - Preclinical, 2014 12 Circadian Technologies Limited - Pipeline by Target, 2014 17 Circadian Technologies Limited - Pipeline by Route of Administration, 2014 18 Circadian Technologies Limited - Pipeline by Molecule Type, 2014 19 Circadian Technologies Limited - Pipeline Products by Mechanism of Action, 2014 20 Circadian Technologies Limited - Recent Pipeline Updates, 2014 21 Circadian Technologies Limited, Subsidiaries 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.